Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cessation of Biologic Treatment in Patients With Takayasu Arteritis in Sustained Remission
NCT07491913Recruiting
- Sponsor
- Marmara University
- Start
- Jun 2025
- Primary completion
- Dec 2027
- Modality
- Antibody Fragments, Antibody Conjugates, Polymer-based Nanoparticles
- Countries
- 1
01
Overview
Open-label, single-arm trial of tocilizumab, infliximab, adalimumab and certolizumab pegol in Takayasu arteritis (TAK), sponsored by Marmara University. Primary endpoint: Proportion of Patients Maintaining Remission After Biologic Treatment Withdrawal at 12 months. Started Jun 2025; status: recruiting.
02
Drugs
03
Conditions
Takayasu arteritis (TAK)
Beyond the preview
Go deeper on NCT07491913.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07491913.